OBJECTIVES . EVG/COBI/FTC/TAF (GENVOYA®) is a single-tablet regimen for the treatment-naive and virologically suppressed HIV-1 infected adult and pediatric patients 12 years of age and older with no known mutations associated with resistance to the individual components of EVG/COBI/FTC/TAF. It contains three different types of HIV drugs: two nucleotide/nucleoside reverse transcriptase inhibitors and one integrase inhibitor. It also contains a pharmacokinetic enhancer, a drug that has no activity against HIV, but boosts the blood levels and effectiveness of other drugs. The objective of this study is to assess the Economic Efficiency of EVG/COBI/FTC/TAF vs the current antiretroviral-naive (RAL+FTC/TDF y EFV and FTC/TDF) regimen in Mexico.

METHODS . Similar efficacy and safety of EVG/COBI/FTC/TAF regarding the current ARV regimens used in Mexico was based on clinical evidence from 3 phase 3 clinical trials. Hence a cost minimization analysis was conducted to assess the expected treatment costs for HIV-1 infection in adults who are antiretroviral therapy-naïve. The costs evaluated included the costs of HIV-1 treatment regimen currently used in Mexico (RAL+FTC/TDF and EFV+FTC/TDF) compared to EVG/COBI/FTC/TAF. The time horizon measured was one year, so no discount rate was considered. The costs are presented in USD. This study was conducted from the institutional perspective.

RESULTS . The evidence and the results form the cost-minimization analysis confirms that EVG/COBI/FTC/TAF the less costly alternative when compared to the current HIV-1 regimen average cost, $4,427.08 ($3,284.37-$4,569.79) vs $6,239.58 ($5,015.62-$6,463.54), respectively. So EVG/COBI/FTC/TAF generates $1,812.50 ($1,731.25-$2,893.75) savings per patient. The base case analysis indicates that adding EVG/COBI/FTC/TAF is a cost-saving alternative. For a cohort of 1,000 patients the potential savings are $1,812,500.00 for the public institutions in Mexico.

CONCLUSIONS . Adding EVG/COBI/FTC/TAF to the Mexican formularies generates important savings for the Mexican healthcare system (since EVG/COBI/FTC/TAF lead to a reduction of direct medical) and provides similar patient outcomes compared to (RAL+FTC/TDF y EFV and FTC/TDF.